2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.
We issued an updated research report on Endo International plc ENDP on Mar 27, 2017. Endo, a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, came into existence ...
- Barrons.com•2 days ago
Gimme Credit is taking drug maker Shire (SHPG) to task today, but not for the load of debt it piled onto its once pristine balance sheet when it acquired U.S. drug make Baxalta last year. Rather, analyst Carol Levenson complains that while company has made progress paying down its management still doesn’t know how to talk to bond investors. According to Levenson, Shire, which unveiled terms of its $32 billion purchase of the Baxter (BAX) spinoff in January 2016, has never released detailed plans for deleveraging its balance sheet.
ENDP : Summary for Endo International plc - Yahoo Finance
Endo International plc (ENDP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||11.25 x 200|
|Ask||11.47 x 100|
|Day's Range||10.71 - 11.55|
|52 Week Range||9.70 - 35.34|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|